{"id":"propranolol-la","safety":{"commonSideEffects":[{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Bradycardia"},{"rate":null,"effect":"Hypotension"},{"rate":null,"effect":"Bronchospasm"},{"rate":null,"effect":"Sexual dysfunction"},{"rate":null,"effect":"Insomnia"}]},"_chembl":{"chemblId":"CHEMBL1671","moleculeType":"Small molecule","molecularWeight":"295.81"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Propranolol competitively inhibits beta-1 and beta-2 adrenergic receptors, reducing heart rate, cardiac contractility, and blood pressure. The long-acting (LA) formulation provides sustained drug release over 24 hours, allowing once-daily dosing. This mechanism makes it effective for managing hypertension, angina, arrhythmias, and other cardiovascular conditions.","oneSentence":"Propranolol is a non-selective beta-adrenergic receptor antagonist that blocks the effects of epinephrine and norepinephrine on the heart and blood vessels.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:30:25.900Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"},{"name":"Angina pectoris"},{"name":"Cardiac arrhythmias"},{"name":"Myocardial infarction secondary prevention"},{"name":"Essential tremor"},{"name":"Migraine prophylaxis"}]},"trialDetails":[{"nctId":"NCT01988883","phase":"EARLY_PHASE1","title":"Modafinil and Cognitive Function in POTS","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2014-10","conditions":"Postural Tachycardia Syndrome","enrollment":20},{"nctId":"NCT03049306","phase":"PHASE2","title":"Propranolol for Sleep Apnea Therapy","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2017-02-15","conditions":"Obstructive Sleep Apnea","enrollment":24},{"nctId":"NCT00647816","phase":"PHASE1","title":"Fasting Study of Propranolol Hydrochloride Extended-Release Capsules 160 mg and Inderal® LA Capsules 160 mg","status":"COMPLETED","sponsor":"Mylan Pharmaceuticals Inc","startDate":"2005-09","conditions":"Healthy","enrollment":100},{"nctId":"NCT00647608","phase":"PHASE1","title":"Food Study of Propranolol Hydrochloride Extended-Release Capsules 160 mg and Inderal® LA Capsules 160 mg","status":"COMPLETED","sponsor":"Mylan Pharmaceuticals Inc","startDate":"2005-09","conditions":"Healthy","enrollment":98},{"nctId":"NCT02620579","phase":"PHASE2","title":"Biopsychosocial Influence on Shoulder Pain","status":"COMPLETED","sponsor":"Duke University","startDate":"2016-01","conditions":"Shoulder Pain","enrollment":264},{"nctId":"NCT04741698","phase":"PHASE1","title":"Propranolol for Protracted Labor","status":"COMPLETED","sponsor":"Christiana Care Health Services","startDate":"2021-07-27","conditions":"Labour;Obstructed, Labor Dystocia","enrollment":80},{"nctId":"NCT01847001","phase":"PHASE2","title":"Study of Propranolol in Newly Diagnosed Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy","status":"COMPLETED","sponsor":"Columbia University","startDate":"2012-10","conditions":"Locally Advanced Malignant Neoplasm, Breast Cancer","enrollment":10},{"nctId":"NCT01555554","phase":"NA","title":"Perioperative Propranolol in Patients With Post Traumatic Stress Disorder (PTSD)","status":"TERMINATED","sponsor":"University of California, San Francisco","startDate":"2012-05","conditions":"Post-traumatic Stress Disorder","enrollment":59},{"nctId":"NCT02420223","phase":"PHASE2","title":"Study of Propranolol to Decrease Gene Expression of Stress-Mediated Beta-Adrenergic Pathways in HCT Recipients","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2015-07-17","conditions":"Multiple Myeloma","enrollment":25},{"nctId":"NCT02495883","phase":"PHASE4","title":"Functional Imaging of Tremor Circuits and Mechanisms of Treatment Response","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2013-12","conditions":"Essential Tremor, Tremor","enrollment":56},{"nctId":"NCT03161964","phase":"PHASE2","title":"Propranolol in Treating Hypoglycemia Unawareness","status":"TERMINATED","sponsor":"Anu Sharma","startDate":"2017-10-19","conditions":"Type 1 Diabetes Mellitus","enrollment":2},{"nctId":"NCT00645450","phase":"PHASE4","title":"PTSD Symptom Reduction by Propranolol Given After Trauma Memory Activation","status":"TERMINATED","sponsor":"VA Office of Research and Development","startDate":"2008-04","conditions":"Posttraumatic Stress Disorders","enrollment":9},{"nctId":"NCT00652600","phase":"PHASE1","title":"Bioavailability Study of Propranolol Under Fed Conditions","status":"COMPLETED","sponsor":"Par Pharmaceutical, Inc.","startDate":"2005-09","conditions":"To Determine Bioequivalence Under Fed Conditions","enrollment":46},{"nctId":"NCT02012777","phase":"PHASE1","title":"Propanolol and Red Cell Adhesion Non-asthmatic Children Sickle Cell Disease","status":"TERMINATED","sponsor":"University of Miami","startDate":"2010-06","conditions":"Sickle Cell Disease","enrollment":9},{"nctId":"NCT00910689","phase":"PHASE4","title":"Drug and Non-Drug Treatment Of Severe Migraine","status":"COMPLETED","sponsor":"Ohio University","startDate":"2001-07","conditions":"Migraine Headache","enrollment":232},{"nctId":"NCT01316952","phase":"","title":"Coreg and HSRs-Updated Analysis","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-06","conditions":"Hypersensitivity","enrollment":1},{"nctId":"NCT00588965","phase":"NA","title":"Effect of Beta-blocker Therapy on QTc Response in Exercise and Recovery in Normal Subjects","status":"COMPLETED","sponsor":"MetroHealth Medical Center","startDate":"2007-08","conditions":"Long QT Syndrome, Cardiac Repolarization","enrollment":36},{"nctId":"NCT01087749","phase":"PHASE1","title":"Pharmacokinetic Study in Patients With Chronic Kidney Disease and Healthy Volunteers","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2010-03","conditions":"Kidney Disease","enrollment":24},{"nctId":"NCT00772031","phase":"PHASE3","title":"NINDS CRC Chronic Migraine Treatment Trial","status":"COMPLETED","sponsor":"Anne Lindblad","startDate":"2008-10","conditions":"Chronic Migraine","enrollment":191},{"nctId":"NCT01069159","phase":"NA","title":"Propranolol Treatment of Traumatic Memories (PTTM)","status":"UNKNOWN","sponsor":"Mela, Mansfield, M.D.","startDate":"2010-02","conditions":"Traumatic Memory, Posttraumatic Stress Disorder","enrollment":66},{"nctId":"NCT00864747","phase":"PHASE1","title":"A Relative Bioavailability Study of Propranolol HCl 160 mg Tablets Under Non-fasting Conditions","status":"COMPLETED","sponsor":"Actavis Inc.","startDate":"2005-05","conditions":"Healthy","enrollment":60},{"nctId":"NCT00865215","phase":"PHASE1","title":"A Relative Bioavailability Study of Propranolol Hydrochloride 160 mg Tablets Under Fasting Conditions","status":"COMPLETED","sponsor":"Actavis Inc.","startDate":"2005-04","conditions":"Healthy","enrollment":60},{"nctId":"NCT00653120","phase":"PHASE2","title":"Bioavailability Study of Propranolol Under Fasting Conditions","status":"COMPLETED","sponsor":"Par Pharmaceutical, Inc.","startDate":"2005-05","conditions":"To Determine Bioequivalence Under Fasting Conditions","enrollment":48}],"_emaApprovals":[],"_faersSignals":[{"count":3,"reaction":"HEADACHE"},{"count":2,"reaction":"AGITATION"},{"count":2,"reaction":"DRUG INEFFECTIVE"},{"count":2,"reaction":"FATIGUE"},{"count":2,"reaction":"HYPOTENSION"},{"count":1,"reaction":"AGGRESSION"},{"count":1,"reaction":"AMMONIA INCREASED"},{"count":1,"reaction":"ARTHRITIS"},{"count":1,"reaction":"BALANCE DISORDER"},{"count":1,"reaction":"BONE DISORDER"}],"_approvalHistory":[],"publicationCount":19,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Inderal LA"],"phase":"phase_3","status":"active","brandName":"Propranolol LA","genericName":"Propranolol LA","companyName":"MetroHealth Medical Center","companyId":"metrohealth-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Propranolol LA is a small molecule that acts as a beta-1 adrenergic receptor antagonist. It has been studied in clinical trials for various conditions, including labor, postural tachycardia syndrome, and shoulder pain.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}